Vivaldi Biosciences, a San Francisco developer of flu vaccines and therapies, raised $2 million in a first round of funding, VentureWire reports (subscription required). The initial funding was raised through Bay City Capital.

Vivaldi is reportedly working on live attenuated vaccines for influenza and a potential drug for treating the flu. The company plans to push some of its candidates into the clinic by the middle of next year, and plans to focus on the elderly, who are particularly susceptible to the flu.